

MONTANA CANCER
CONTROL PROGRAMS

Cancer in Montana 2003-2007

**Montana Central Tumor Registry
Annual Report**

**November 2009
Helena, Montana**



Cancer in Montana 2003-2007

An Annual Report of the
Montana Central Tumor Registry

November 2009

For more information contact:

Montana Central Tumor Registry
Department of Public Health and Human Services
Public Health and Safety Division
PO Box 202952
Helena, MT 59620
Phone: (406) 444-2618
Fax: (406) 444-6557
Website:
www.cancer.mt.gov

Prepared by:

Debbi Lemons, RHIA, CTR
Coordinator
Montana Central Tumor Registry

Carol Ballew, PhD, Epidemiologist
Program Manager
Cancer Surveillance and Epidemiology Program



This page intentionally left blank

DEPARTMENT OF
PUBLIC HEALTH AND HUMAN SERVICES



Brian Schweitzer
GOVERNOR

Anna Whiting Sorrell
DIRECTOR

STATE OF MONTANA

www.dphhs.mt.gov

PO BOX 4210
HELENA, MT 59604-4210
(406) 444-5622
FAX (406) 444-1970

November 2009

Dear Colleagues and Citizens,


The Montana Department of Public Health and Human Services (DPHHS) is pleased to provide you the Cancer in Montana – 2003-2007 – Montana Central Tumor Registry Annual Report.

This publication was made possible through generous commitment and cooperation among Montana hospitals, cancer registrars, physicians, pathologists, the Montana Office of Vital Statistics, and the Centers for Disease Control and Prevention's National Program of Cancer Registries (NPCR). The Montana Cancer Registrars' Association is acknowledged for supporting the Montana Central Tumor Registry (MCTR) and helping to provide vital training to Montana's cancer registrars.

The MCTR is an integral component of Montana's Comprehensive Cancer Control plan. The Montana Cancer Control Coalition (MTCCC) took root in October 2003 when many people came together to identify priority issues for cancer control in Montana. DPHHS is a supporting partner to the MTCCC. Comprehensive Cancer Control is broadly defined as "a coordinated approach to reduce the incidence, morbidity and mortality of cancer through prevention, early detection, treatment, rehabilitation and palliation." The MTCCC developed the Montana Comprehensive Cancer Control (CCC) Plan as a guide for preventing and controlling cancer in Montana. To find more information about the MTCCC, the plan, and to access the Cancer in Montana – 2003-2007 – Montana Central Tumor Registry Annual Report, visit www.cancer.mt.gov.

We hope that you will find this report useful. If you have any questions or need more information please contact Debbi Lemons by e-mail at dlemons@mt.gov or by phone at (406) 444-6786.

Sincerely,


Anna Whiting Sorrell
DPHHS Director

An Equal Opportunity Employer



This page intentionally left blank

Table of Contents

Executive Summary.....	iii
Acknowledgments.....	.v
Confidentiality of Cancer Information.....	vii
Introduction.....	.1
Cancer Among American Indian Residents of Montana, 2003-2007.....	.5
Summaries for Specific Cancers	
All Sites Combined	10
Prostate	12
Lung and Bronchus	14
Breast (female)	16
Colon and Rectum	18
Cervix	20
Appendices	
A. Overview of the Montana Central Tumor Registry	25
B. Technical Notes and Definitions	29
C. Stage at Diagnosis	31
D. County Incidence Rates for All Sites Combined	34
E. Count of Cancers Reported by Anatomical Site and Sex	35
F. Montana Population by County, 2000 Census	36
Montana Population Estimates by Year, Age, and Sex, 2003-2007	37
2000 Standard Million Population	38
G. ICD-O-3 Codes by Anatomical Site	39
H. Resources	42

This page intentionally left blank

Executive Summary

Cancer is the second leading cause of death among Montana residents, after diseases of the circulatory system such as heart disease and stroke. Four sites -- prostate, lung and bronchus, female breast, and colon and rectum -- accounted for 58% of all reported cancers in Montana in the interval 2003-2007.

Montana's cancer burden is lower than that of the United States as a whole for all sites combined and for many individual sites. However, more can be done to further reduce the cancer burden in Montana.

- The single greatest cancer prevention measure that can be implemented is smoking prevention or cessation.
 - ✓ More than 85% of cases of cancer of the lung and bronchus are attributable to cigarette smoking and exposure to second-hand smoke. These cancers, accounting for 15% of all newly diagnosed cases in Montana, are therefore almost entirely preventable.
 - ✓ Cigarette smoking also increases the risk of cancers of the sinuses, mouth, throat, liver, pancreas, stomach, kidneys, bladder, colon and rectum, and cervix.
 - ✓ One third of all cancer deaths in Montana are caused by cigarettes.
- Screening for breast, cervical, and colorectal cancer saves lives, either by finding cancer at an early stage when it is most treatable, or by finding and treating precancerous lesions so they do not progress to cancer.
 - ✓ Invasive cervical cancer has been almost eliminated by the widespread use of screening.
 - ✓ Approximately 80% of colorectal cancer could be prevented by colonoscopic screening that can find and remove polyps and other precancerous growths.
 - ✓ More than 95% of women whose breast cancer is diagnosed at the local stage survive for five or more years after diagnosis, compared to fewer than 25% of women whose cancer is diagnosed at the distant stage.

This page intentionally left blank

Acknowledgments

This report would not be possible without the efforts of the Montana Central Tumor Registry staff and the personnel at all reporting facilities that diagnose or treat patients with reportable cancers in Montana. The Montana Central Tumor Registry receives cancer and other tumor reports from many sources: hospitals, radiation treatment centers, physicians, pathology laboratories, the Montana Office of Vital Statistics, and other states where Montana residents go for diagnosis or treatment. Their contribution and cooperation is acknowledged and sincerely appreciated.

Bruce Schwartz and David Fulgham, statisticians in the Office of Vital Statistics, are acknowledged for their contribution of Montana mortality data. Mortality data for 2003-2007 were provided and used to calculate Montana mortality rates.

The Montana Central Tumor Registry would also like to acknowledge its funding sources. The Montana Central Tumor Registry is funded in part by the Montana State General Fund and in part by the Centers for Disease Control - National Program of Cancer Registries (NPCR) under Cooperative Agreement DP07-703 93.283.

This page intentionally left blank

Confidentiality of Cancer Information

Confidentiality is of vital importance to the Montana Central Tumor Registry. The privacy of patients and reporting hospitals, laboratories, and physicians is strictly maintained. Confidentiality is an issue of increasing concern to cancer registries. Montana state statutes, federal laws, and the policies of the Montana Central Tumor Registry prohibit the release of any individually identifiable information to third parties.

Montana cancer data are published only in statistically summarized form so that individual patients, hospitals, or physicians cannot be identified or re-identified through linkage to other data sources. To protect privacy, and to insure reliable statistical estimates, the Montana Central Tumor Registry suppresses rates and counts if there are fewer than five cases or if the relative standard error around an estimated rate is greater than 25% of the estimate. In general, this means that county-level and race-specific data are unavailable, apart from All Sites Combined. More detailed data may be requested by county health departments and health care organizations.

The Montana Central Tumor Registry has recently formed a Data Use Review Committee to act on requests for data sets and make recommendations on data use. The goal of this committee is to make Montana cancer data available for public health activities and research while protecting the confidentiality of individual data. Data sharing policies and procedures for requesting data sets can be found at www.cancer.mt.gov under the link to the Cancer Surveillance and Epidemiology Program.

To further protect confidential information, the Montana Central Tumor Registry is increasingly receiving data in electronic formats. Electronic files can be submitted through the State of Montana File Transfer Service, which is protected under a Secure Socket Layer and meets national and state standards for electronic data transfer using AES encryption and is approved by National Institutes of Standards and Technology (NIST) for FIPS 140-2 level 2 uses. The Montana Central Tumor Registry fax is also electronically secure. Any fax received is automatically saved to a secure server and not printed on a fax machine.

This page intentionally left blank

Introduction

Cancer is a general term for cells that grow out of control, no longer perform their normal functions, and invade other tissues. The Montana Central Tumor Registry collects data on all cancers diagnosed in patients who are residents of Montana or residents of other states who are diagnosed or treated for cancer in Montana.

Cancer was the second leading cause of death in Montana from 2003 through 2007, after diseases of the circulatory system such as heart disease and stroke. A total of 27,612 tumor cases were reported to the Montana Central Tumor Registry in this interval, including invasive and in-situ cancers, benign tumors, and tumors of uncertain behavior. Invasive tumors accounted for 23,414 cases (85%); carcinoma in-situ accounted for 3,658 cases (13%). Cancers were reported for 44 primary anatomical sites and in 918 cases the origin (primary site) of the cancer was unknown or not clearly defined.


Four sites (prostate, lung and bronchus, female breast, and colon and rectum) accounted for 58% of all incident cancers in Montana from 2003 through 2007. Cancer at the remaining 40 sites was relatively rare and only 17 sites accounted for more than 1% of all cancers. A complete tabulation of cancers reported to the Montana Central Tumor Registry is presented in Figure 1 and Table 1.

This report provides detailed summaries for All Sites Combined and the four most common types of cancer diagnosed among Montana residents (prostate, lung and bronchus, female breast, and colon and rectum), plus cervical cancer. Although invasive cervical cancer is now rare, it was the most common cause of cancer death among women in the United States through the first part of the twentieth century. Since the widespread use of the Papanicolaou (Pap) smear screening test was institutionalized in the 1950s, most women are spared ever developing cervical cancer because precancerous lesions are found and treated. However, a decline in Pap screening participation could lead to an upturn in the incidence of invasive cervical cancer, so this is monitored closely.

The summaries include age-adjusted incidence and mortality rates for Montana and the United States, stage at diagnosis, age-specific incidence rates by sex, 10-year incidence trends, and relative survival for Montana residents. All rates are age-adjusted to the 2000 standard million population.¹ These rates are not comparable to rates age-adjusted to any other reference population. For example, in the past it was conventional to adjust rates using the 1970 standard million population.

¹ See Appendix F. See also R. N. Anderson and H. M. Rosenberg, Age Standardization of Death Rates: Implementation of the Year 2000 Standard. National Vital Statistics Report, Vol 47, no. 3. Hyattsville, MD: National Center for Health Statistics, 1998.

Figure 1. Ranked Cumulative Percent of Invasive Cancers by Anatomical Site#, Montana 2003-2007



See site groupings on next page.

^ Sites were ranked in descending order according to their respective percentage of the total number of invasive cancer cases. Then cumulative percentages were computed and graphed. To read this graph, examine the y-axis, for example 50%, and drop an imaginary line down to the x-axis, in this case rank number 3. This tells you that three cancer sites (prostate, lung & bronchus, and breast) account for 50% of invasive cancer cases, according to this grouping. Similarly, eight sites account for approximately 75% of all cases.

Table 1. Ranked Cumulative Percent of Invasive Cancers by Anatomical Site, 2003-2007

Rank	Anatomical Site Grouping*	MALE	FEMALE	Percent of Total Cases	Ranked Cumulative Percent	Incidence Rate ***	95% Confidence Interval	
1	Prostate	4,253		18.42%	18.42%	167.6	162.5 - 172.7	†
2	Lung & Bronchus	1,768	1,631	14.73%	33.15%	64.7	62.5 - 66.9	‡
3	Breast	18	3,280	14.29%	47.44%	62.4	60.3 - 64.6	‡
4	Colon & Rectum	1,214	1,136	10.18%	57.62%	44.2	42.4 - 46.0	‡
5	Bladder**	909	268	5.10%	62.72%	22.1	20.9 - 23.4	
6	Non-Hodgkin Lymphoma*	539	410	4.11%	66.83%	18.1	17.0 - 19.3	
7	Melanoma	488	394	3.82%	70.65%	17.3	16.1 - 18.4	
8	Leukemia	395	282	2.93%	73.58%	13.2	12.2 - 14.2	
9	Kidney & Renal Pelvis	404	239	2.79%	76.37%	12.3	11.3 - 13.2	‡
10	Uterus		634	2.75%	79.11%	22.5	20.8 - 24.3	
11	Pancreas	314	286	2.60%	81.71%	11.1	10.2 - 12.0	
12	Oral Cavity & Pharynx	392	152	2.36%	84.07%	10.1	9.3 - 11.0	
13	Thyroid	122	406	2.29%	86.36%	10.9	10.0 - 11.8	†
14	Ovary		378	1.64%	88.00%	13.3	12.0 - 14.7	
15	Brain & Other CNS	217	138	1.54%	89.53%	7.0	6.2 - 7.7	
16	Stomach	182	108	1.26%	90.79%	5.4	4.8 - 6.1	‡
17	Multiple Myeloma	155	126	1.22%	92.01%	5.3	4.7 - 5.9	
18	Esophagus	194	57	1.09%	93.09%	4.6	4.0 - 5.2	
19	Liver & Bile Duct	127	70	0.85%	93.95%	3.6	3.1 - 4.2	‡
20	Larynx	123	45	0.73%	94.68%	3.1	2.6 - 3.6	‡
21	Soft Tissue	82	68	0.60%	95.27%	3.0	2.5 - 3.5	
22	Cervix		138	0.56%	95.83%	5.5	4.5 - 6.4	‡
23	Testis	129		0.65%	96.48%	5.9	4.9 - 7.0	
24	Hodgkin Lymphoma*	70	43	0.49%	96.97%	2.4	1.9 - 2.8	
25	Small Intestine	35	38	0.32%	97.29%	1.4	1.1 - 1.7	‡
26	Vulva		73	0.29%	97.58%	2.5	2.0 - 3.1	
27	Anus & Anal Canal	22	46	0.26%	97.85%	1.3	1.0 - 1.6	
28	Other Biliary	34	27	0.32%	98.16%	1.2	0.9 - 1.5	‡
29	Other Skin Cancers	22	31	0.23%	98.39%	1.0	0.8 - 1.3	‡
30	Eye	31	21	0.23%	98.62%	1.0	0.7 - 1.3	
31	Bones & Joints	25	26	0.22%	98.84%	1.0	0.7 - 1.3	
32	Gallbladder	12	30	0.18%	99.02%	0.8	0.6 - 1.0	‡
33	Other Endocrine	22	19	0.18%	99.20%	0.8	0.6 - 1.1	
34	Peritoneum	~	32	0.15%	99.35%	0.7	0.4 - 0.9	
35	Nasal Cavity & Sinuses	18	7	0.11%	99.46%	0.5	0.3 - 0.6	‡
36	Retroperitoneum	5	17	0.09%	99.55%	0.4	0.2 - 0.6	
37	Ureter	13	8	0.10%	99.64%	0.4	0.2 - 0.6	
38	Penis	18		0.07%	99.72%	0.7	0.4 - 1.0	
39	Other Female Genital Organs		17	0.08%	99.80%	0.7	0.4 - 1.0	
40	Vagina		17	0.07%	99.87%	~	~	
41	Other Digestive Organs	6	7	0.06%	99.93%	0.3	0.1 - 0.4	
42	Trachea & Pleura	7	~	0.04%	99.97%	~	~	
43	Other Urinary Organs	~	~	0.02%	99.99%	~	~	
44	Other Male Genital Organs	~		0.01%	100.00%	~	~	
	Total Excluding Unknowns	12,365	10,705	100.00%				
	Unknown and Ill-defined Sites	501	417			17.4	16.3 - 18.6	
	Total Invasive Cancers	12,866	11,122			455.5	449.6 - 461.3	‡

* Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma are not included in the anatomical site (e.g., lymphoma of the stomach is counted as a lymphoma, not stomach cancer).

** Incidence includes all invasive cases plus bladder in-situ cases.


*** Per 100,000, age-adjusted to the 2000 Standard Million

~ Indicates fewer than 5 cases or relative standard error greater than 25% of estimated rate

† Montana rate statistically significantly higher than US rate. ‡ Montana rate statistically significantly lower than US rate.

Montana's cancer incidence or mortality or both were lower than those of the United States as a whole for all sites combined, for three of the four most common sites (lung and bronchus, female breast, and colorectal), and for many other sites (kidney, oral cavity, stomach, liver, larynx, cervix, and small intestine) (Table 1 and Figure 2). Montana's incidence of prostate and thyroid cancer were higher than those of the United States. Rates at other sites were not different.

Figure 2. Montana Cancer Incidence and Mortality Rates Relative to the United States



Standardized incidence and mortality ratios. Ratios less than 1.0 indicate Montana rates are lower than national rates. Ratios greater than 1.0 indicate Montana rates are higher than national rates. Statistically significant differences are indicated by † for incidence rates and § for mortality rates.

Cancer Among American Indian Residents of Montana, 2003-2007

Identifying American Indian Patients in the Montana Central Tumor Registry

American Indians are often misclassified in health records systems, including tumor registries. This underestimates the cancer burden of American Indians. Montana and 45 other states collaborate with the Indian Health Service (IHS) Division of Epidemiology to perform annual records linkages between state tumor registry files and IHS administrative files from 1990 forward. Each year the Montana Central Tumor Registry reclassifies an average of 25 to 30 patients to American Indian through this process. This greatly improves the accuracy of cancer data for American Indian residents of Montana.

Computing Cancer Incidence Rates for American Indians

Montana has a relatively small population overall, approximately 920,000 in 2007. There are fewer than 70,000 American Indian residents of Montana, 7% of the total population, with fewer than 200 cases of cancer per year. Small numbers yield statistically unreliable rates that fluctuate substantially from year to year. Apart from All Sites Combined, the relative standard errors around the incidence rates for American Indians (Table 2) are greater than 25%, indicating a large margin of error around the rate.

Cancer Incidence Among American Indian Residents of Montana

The most common incident cancers among American Indian residents of Montana are the same as those for the state as a whole: prostate, breast, lung and bronchus, and colon and rectum. The incidence rates of prostate and breast cancers among American Indian residents are not statistically significantly different than the statewide incidence rates. American Indian residents have statistically significantly higher incidence rates of lung, colorectal, kidney, stomach, and liver cancers.

The disparities in cancer incidence between American Indian and other residents of Montana are associated with differences in lifestyle and screening participation. Approximately 85% of cases of **lung cancer** are attributable to smoking cigarettes; 54% of American Indian adults in Montana smoke, compared to 14% of White adults in Montana.² Smoking is also a risk factor for **stomach and kidney cancers**.

Infection with *Helicobacter pylori* is a risk factor for **stomach cancer**. *H. pylori* is a bacterium that infects the lining of the stomach and causes chronic irritation. Irritation can lead to ulcers and stomach cancer.³ Among American Indian residents of Montana, the kinds of stomach cancer associated with *H. pylori* account for one half of all cases, while among White residents they account for only one third of all cases. This is consistent with studies of stomach cancer among American Indians in other parts of the United States.⁴ *H. pylori*

2 Montana Tobacco Use Prevention Program. 2009. Adult Tobacco Use in Montana. *Results of the 2008 Montana Adult Tobacco Survey*. Helena, MT.

3 McNamara, D, El-Omar, E. 2008. *Dig Liver Dis* epub May 15, 2008.

4 Wiggins et al. 2008. *Cancer* 113(Suppl 5):1225-1233.

Table 2. Cancer Incidence Statewide and Among American Indian Residents of Montana, 2003-2007

	Statewide		American Indian		
	Incidence *	95% CI **	Incidence	95% CI §	
All sites	455.5	449.6 - 461.3	527.5	491.7 - 563.3	†
Prostate	167.6	162.5 - 172.7	134.1	104.7 - 163.6	
Breast (female)	119.5	115.3 - 123.6	121.1	99.9 - 142.3	
Lung and bronchus	64.7	62.5 - 66.9	97.2	81.3 - 113.0	†
Colon and rectum	44.2	42.4 - 46.0	62.7	50.0 - 75.4	†
Uterus	22.5	20.8 - 24.3	26.2	15.6 - 36.8	
Bladder	22.1	20.9 - 23.4	18.9	11.5 - 26.3	
Non-Hodgkin lymphoma	18.1	17.0 - 19.3	21.9	14.1 - 29.8	
Melanoma	17.3	16.1 - 18.4	4.6	1.4 - 7.9	‡
Ovary	13.3	12.0 - 14.7	11.9	5.0 - 18.9	
Leukemia	13.2	12.2 - 14.2	12.2	6.6 - 17.7	
Kidney and renal pelvis	12.3	11.3 - 13.2	23.1	16.5 - 29.8	†
Pancreas	11.1	10.2 - 12.0	13.8	7.7 - 19.8	
Thyroid	10.9	10.0 - 11.8	7.0	3.8 - 10.3	
Brain and other CNS	7.0	6.2 - 7.7	7.5	3.6 - 11.4	
Cervix	5.5	4.5 - 6.4	7.5	2.8 - 12.2	
Stomach	5.4	4.8 - 6.1	14.7	8.9 - 20.5	†
Multiple myeloma	5.3	4.7 - 5.9	8.1	3.7 - 12.5	
Esophagus	4.6	4.0 - 5.2	3.8	0.6 - 7.1	
Liver and bile duct	3.6	3.1 - 4.2	14.2	8.5 - 19.9	†

Sites account for 80% of all cancers statewide and for 85% of all cancers among American Indians.

* Incidence rates per 100,000 population, age-adjusted to the 2000 Standard Population.

** CI = Confidence Interval. True incidence is within this range with 95% certainty.

§ Apart from All Sites Combined, all relative standard errors computed for American Indian incidence rates are greater than 25% of the point estimate.

† Indicates that American Indian incidence rate is statistically significantly higher than statewide incidence rate.

‡ Indicates that American Indian incidence rate is statistically significantly lower than statewide incidence rate.

infection is usually acquired in childhood or adolescence and usually lasts throughout life. It is less common in more affluent communities and more common where community sanitation is poor and housing conditions are crowded.⁵




Cirrhosis of the liver (chronic inflammation and fibrosis from several causes) increases the risk of **liver cancer**. The most common causes of cirrhosis are alcohol abuse and chronic infection with Hepatitis B or C. Even moderate alcohol consumption in combination with chronic hepatitis can cause cirrhosis. The National Cancer Institute recommends Hepatitis B vaccination to reduce the risk of liver cancer.⁶

5 Brown LM. 2000. *Epidemiol Rev* 22:283-297.

6 <http://www.cancer.gov/pdq/prevention/hepatocellular/HealthProfessional/page2>

Colorectal cancer is almost entirely preventable by endoscopic screening. Among American Indian adults in Montana age 50 years and older, 43% have ever had an endoscopy, compared to 57% of White adults age 50 and older in Montana.⁷

Cancer survival among American Indian residents of Montana is slightly lower than survival for all residents for patients diagnosed between 1998 and 2002 (to allow time for at least five years of survival) (Figure 3). The lower survival is attributable in part to later stage at diagnosis among American Indian patients, which did not improve between 1998-2002 and 2003-2007 (Figures 4 and 5).



7 Montana Behavioral Risk Factor Surveillance System, 2008 Survey. <http://74.205.72.25/html/brfss-index.shtml>

This page intentionally left blank

Summary Tables

All Sites Combined

Prostate

Lung and Bronchus

Breast (female)

Colon and Rectum

Cervix

All Sites Combined

Incidence and Mortality Summary^a


Incidence	Incidence Rate ^b		
	Male †	Female †	Total †
U.S.	558.9	414.8	473.7
Montana	523.1	401.7	455.5
95% CI	(513.9 - 532.2)	(394.2 - 409.3)	(449.6 - 461.3)

No. of Cases:	Montana only		
	Male	Female	Total
Invasive	12,418	10,996	23,414
In-Situ	1,231	2,427	3,658
Uncertain	41	69	110
Benign	155	275	430

Mortality	Mortality Rate ^b		
	Male †	Female †	Total †
U.S.	234.4	159.9	189.8
Montana	208.8	154.7	177.2
95% CI	(203.0 - 214.6)	(150.2 - 159.2)	(173.6 - 180.7)

No. of Deaths:	Montana only		
	Male	Female	Total
All Cancers	4,917	4,513	9,430

Stage at Diagnosis



* SEER data for stage at diagnosis are unavailable for all cancers combined.

† Montana rates are statistically significantly lower than U.S. rates.

a Rates include all invasive cases plus bladder in-situ cases.

b Incidence and mortality rates are per 100,000 age-adjusted to the 2000 Standard Million Population. Montana age-adjusted rates are for 2003-2007; U.S. age-adjusted rates are for 2001-2005 based on USCS.

Risk and Associated Factors

Age: As we age, we are more likely to develop cancer. Cancer is most often found in people over the age of 60.

Sex: Looking at all cancers combined, men are more likely to be diagnosed with a cancer than women.


Race: Looking at all cancers, African Americans are more likely to be diagnosed with cancer than people of other races.

Family history and genetics: Many kinds of cancer tend to recur in families, and a family history of cancer in a near relative is a risk factor for developing that kind of cancer. However, it is often not clear whether familial aggregation of cancer is due to shared environments, shared genetic predispositions, or both. Some cancers are associated with specific genetic conditions or mutations, but these account for a very small proportion of cancers. More than 90% of all cancers are sporadic, that is, not due to an inherited genetic susceptibility.


Prevention: Healthy lifestyles can substantially reduce the risk of cancer. The risk of developing many kinds of cancer increases with smoking, obesity, high-fat and low-fiber diets, and a sedentary lifestyle. In addition, screening and early detection can find cancers or precursor lesions at an early stage, when they are the most treatable.

All Sites Combined


Age-Specific Incidence Rates



Ten-Year Trend^c, 1998-2007



Relative Survival, 1998-2007



^c Confidence intervals (95%) are shown with vertical bar.

Prostate

Incidence and Mortality Summary^a


Incidence	Incidence Rate ^b		
	Male ‡	Female	Total
U.S.	156.7	-	-
Montana	167.6	-	-
95% CI	(162.5 - 172.7)	-	-

No. of Cases:	Montana only		
	Male	Female	Total
Invasive	4,253	-	-
In-Situ	381	-	-
Uncertain	0	-	-
Benign	0	-	-

Mortality	Mortality Rate ^b		
	Male	Female	Total
U.S.	26.7	-	-
Montana	27.7	-	-
95% CI	(25.5 - 29.9)	-	-

No. of Deaths:	Montana only		
	Male	Female	Total
Prostate	609	-	-

Stage at Diagnosis^c



Risk and Associated Factors

Age: Age is the strongest risk factor for prostate cancer, with most men diagnosed after age 65.

Race: African American men are more likely to be diagnosed with prostate cancer than men of other races.

Diet: A diet high in animal fat or low in fruits and vegetables may increase the risk of prostate cancer.

Family History: Risk of prostate cancer increases if a man's father or brother had the disease.

^a Rates include invasive cancers only.


^b Incidence and mortality rates are per 100,000 age-adjusted to the 2000 Standard Million Population. Montana age-adjusted rates are for 2003-2007; U.S. age-adjusted rates are for 2001-2005 based on USCS.

^c Montana stage at diagnosis are for 2003-2007; SEER data for stage at diagnosis are 1999-2005.


‡ Montana rate is statistically significantly higher than U.S. rate.

Prostate


Age-Specific Incidence Rates



Ten-Year Trend^d, 1998-2007



Relative Survival, 1998-2007



^d Confidence intervals (95%) are shown with vertical bar.

Lung and Bronchus

Incidence and Mortality Summary^a


Incidence	Incidence Rate ^b		
	Male †	Female	Total †
U.S.	87.8	55.3	69.1
Montana	73.6	58.1	64.7
95% CI	(70.1 - 77.0)	(55.2 - 60.9)	(62.5 - 66.9)

No. of Cases:	Montana only		
	Male	Female	Total
Invasive	1,768	1,631	3,399
In-Situ	~	~	~
Uncertain	~	0	~
Benign	0	0	0

Mortality	Mortality Rate ^b		
	Male †	Female	Total †
U.S.	72.0	41.0	54.1
Montana	60.0	43.1	50.4
95% CI	(56.9 - 63.1)	(40.7 - 45.5)	(48.6 - 52.4)

No. of Deaths:	Montana only		
	Male	Female	Total
Lung & Bronch	1,427	1,229	2,656

Stage at Diagnosis^c



^a Rates include invasive cases only.

^b Incidence and mortality rates are per 100,000 age-adjusted to the 2000 Standard Million Population. Montana age-adjusted rates are for 2003-2007; U.S. age-adjusted rates are for 2001-2005 based on USCS.

^c Montana stage at diagnosis are for 2003-2007; SEER data for stage at diagnosis are 1999-2005.

† Montana rates statistically significantly lower than U.S. rates.

~ Counts are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Risk and Associated Factors

Lung cancer is the most commonly diagnosed cancer worldwide and the most common cause of cancer death. It is almost entirely preventable because nearly all cases can be attributed to avoidable risk factors.


Smoking and Exposure to Secondhand Smoke: 90% of all cases of lung cancer are attributable to cigarette smoking. The remaining 10% is attributable to exposure to second hand smoke or radon.

Occupation: People exposed to asbestos are at increased risk of developing lung cancer. Those who smoke and are exposed to asbestos are at even greater risk.


Environment: Exposure to radon increases the risk of developing lung cancer. People who smoke and are exposed to radon are at even greater risk. Some regions have high levels of naturally occurring radon which may enter homes. Simple home test kits are available.

Lung and Bronchus


Age-Specific Incidence Rates



Ten-Year Trend^d, 1998-2007



Relative Survival, 1998-2007



^d Confidence intervals (95%) are shown with vertical bar.

Breast (female)

Incidence and Mortality Summary^a


Incidence	Incidence Rate ^b		
	Male	Female	Total
U.S.	-	123.0	-
Montana	-	119.5	-
95% CI	-	(115.3 - 123.6)	-

No. of Cases:	Montana only		
	Male	Female	Total
Invasive	-	3,280	-
In-Situ	-	799	-
Uncertain	-	0	-
Benign	-	0	-

Mortality	Mortality Rate ^b		
	Male	Female †	Total
U.S.	-	25.0	-
Montana	-	21.2	-
95% CI	-	(19.5 - 22.9)	-

No. of Deaths:	Montana only		
	Male	Female	Total
Breast	-	613	-

Stage at Diagnosis^c



Risk and Associated Factors

Age: Age is the most important risk factor for breast cancer. Incidence increases rapidly from age 20 through 50, then levels off slightly.

Race: Overall, breast cancer is more common in white women compared to women of other races, although it is more common in younger black women than younger white women.

Physical Activity: Women who are physically inactive throughout life appear to have an increased risk of breast cancer.

Obesity: Women who are obese after menopause have an increased risk of breast cancer.

Genetics: Breast cancer in a first-degree female relative is a risk factor for breast cancer. Between 5% and 10% of breast cancer has been attributed to specific genetic mutations, including the BRCA1 or BRCA2 genes. However, 90% or more of newly diagnosed cases of breast cancer occur in women who do not have a known family history of breast cancer and who do not have a recognized genetic mutation.

Family History: A woman's risk increases if she has a history of breast cancer in her family, especially if her mother, sister or daughter had breast cancer before the age of 40.

Reproductive History: The risk of breast cancer is increased among women who experience menarche at an early age, women who experience menopause at a late age, and women who have never had children. These effects are believed to be mediated by estrogen. Early first full-term pregnancy, higher number of births, and breastfeeding reduce the risk for breast cancer.

^a Rates include invasive cases only.


^b Incidence and mortality rates are per 100,000 age-adjusted to the 2000 Standard Million Population. Montana age-adjusted rates are for 2003-2007; U.S. age-adjusted rates are for 2001-2005 based on USCS.

^c Montana stage at diagnosis are for 2003-2007; SEER data for stage at diagnosis are 1999-2005.


† Montana rate statistically significantly lower than U.S. rates.

Breast (female)


Age-Specific Incidence Rates



Ten-Year Trend^d, 1998-2007



Relative Survival, 1998-2007



^d Confidence intervals (95%) are shown with vertical bar.

Colon & Rectum

Incidence and Mortality Summary^a


Incidence	Incidence Rate ^b		
	Male †	Female †	Total †
U.S.	60.8	44.5	51.6
Montana	49.9	39.3	44.2
95% CI	(47.0 - 52.7)	(37.0 - 41.6)	(42.4 - 46.0)

No. of Cases:	Montana only		
	Male	Female	Total
Invasive	1,214	1,136	2,350
In-Situ	111	76	187
Uncertain	15	28	43
Benign	0	0	0

Mortality	Mortality Rate ^b		
	Male †	Female †	Total †
U.S.	22.7	15.9	18.8
Montana	18.0	14.2	15.9
95% CI	(16.3 - 19.7)	(12.8 - 15.6)	(14.8 - 17.0)

No. of Deaths:	Montana only		
	Male	Female	Total
Colon & Rectum	424	430	854

Stage at Diagnosis^c



^a

^a Rates include invasive cases only.

^b Incidence and mortality rates are per 100,000 age-adjusted to the 2000 Standard Million Population. Montana age-adjusted rates are for 2003-2007; U.S. age-adjusted rates are for 2001-2005 based on USCS.

^c Montana stage at diagnosis are for 2003-2007; SEER data for stage at diagnosis are 1999-2005.

† Montana rates statistically significantly lower than U.S. rates.

Risk and Associated Factors

Age: The incidence of colorectal cancer begins to increase around age 35 but increases most rapidly after age 50 and peaks after age 70. Ninety percent of all colorectal cancers are diagnosed after age 50.

Sex: Males are diagnosed with colorectal cancer slightly more than females.

Race: African Americans are diagnosed with colorectal cancer slightly more than other races.

Diet: A diet high in fat and low in fruits and vegetables may increase the risk of colorectal cancer.


Smoking: People who smoke are more likely to develop polyps and colorectal cancer.

Polyps: Polyps, or growths on the inner wall of the colon or rectum, are common in people over 50. Most are benign, but some polyps can develop into cancer.


Genetics: People who have a parent or sibling with colorectal cancer are more likely to develop colorectal cancer themselves. Changes in specific genes, such as the hereditary nonpolyposis colon cancer (HNPCC) gene or the adenomatous polyposis controller (APC) gene, increase the risk of colorectal cancer. Genetic predisposition accounts for a small proportion of cases of colon cancer.

Colon & Rectum


Age-Specific Incidence Rates



Ten-Year Trend^d, 1998-2007



Relative Survival, 1998-2007



^d Confidence intervals (95%) are shown with vertical bar.

Cervix

Incidence and Mortality Summary^a


Incidence	Incidence Rate ^b		
	Male	Female †	Total
U.S.	-	8.5	-
Montana	-	5.5	-
95% CI	-	(4.5 - 6.4)	-

No. of Cases:	Montana only		
	Male	Female	Total
Invasive	-	138	-
In-Situ	-	1,046	-
Uncertain	-	0	-
Benign	-	0	-

Mortality	Mortality Rate ^b		
	Male	Female †	Total
U.S.	-	2.5	-
Montana	-	1.9	-
95% CI	-	(1.3 - 2.4)	-

No. of Deaths:	Montana only		
	Male	Female	Total
Cervix	-	51	-

Stage at Diagnosis^c



Risk and Associated Factors

Age: Invasive cervical cancer occurs most often in women over 40 but precursor lesions may occur at younger ages. Regular cytological screening with the Papanicolaou (Pap) test has reduced the incidence of invasive cervical cancer and increased the discovery and treatment of precancerous lesions among younger women.

Race: Hispanic women have the highest rates of cervical cancer followed by African Americans, Asians, whites, and American Indians.

Human papillomaviruses (HPVs): HPV has emerged as a necessary but not sufficient risk factor for cervical cancer. HPV infections are very common but more than 90% of such infections spontaneously disappear with no apparent ill-effects. A small proportion of women develop persistent infections that confer increased risk of cervical cancer, but additional risk factors seem to be required for invasive cancer to develop.

Other Factors: Cofactors that appear to act together with persistent HPV infection to increase the risk of cervical cancer include the number of lifetime sexual partners, prolonged (10 or more years) use of oral contraceptives, high parity, and cigarette smoking.

^a Rates include invasive cases only.


^b Incidence and mortality rates are per 100,000 age-adjusted to the 2000 Standard Million Population. Montana age-adjusted rates are for 2003-2007; U.S. age-adjusted rates are for 2001-2005 based on USCS.

^c Montana stage at diagnosis are for 2003-2007; SEER data for stage at diagnosis are 1999-2005.


† Montana rates statistically significantly lower than U.S. rates.

Cervix


Age-Specific Incidence Rates



Ten-Year Trend^d, 1998-2007



Relative Survival, 1998-2007



^d Confidence intervals (95%) are shown with vertical bar.

This page intentionally left blank

Appendices

- A. Overview of the Montana Central Tumor Registry
- B. Technical Notes and Definitions
- C. Stage at Diagnosis
- D. County Incidence Rates for All Sites Combined
- E. Count of Cancers Reported by Anatomical Site and Sex
- F. Montana Population by County, 2000 Census

Montana Population Estimates by Year, Age, and Sex, 2003 - 2007

2000 Standard Million Population

- G. ICD-O-3 Codes by Anatomical Site
- H. Resources

This page intentionally left blank

Appendix A

Overview of the Montana Central Tumor Registry

Purpose of the Montana Central Tumor Registry

The Montana Central Tumor Registry is a central state registry of all cancers diagnosed and/or treated in Montana. The Montana Central Tumor Registry uses a computer data system designed for the collection, storage, management, and analysis of the data collected and maintained.

Central cancer registries are organizations that collect, store, analyze, and interpret cancer data on people who are diagnosed and/or treated for cancer in population-based areas. The primary objective of the Montana Central Tumor Registry is to analyze the incidence, mortality, survival, and the changing frequency of cancer in Montana residents. Analysis is possible with complete, timely and quality data reporting.

Follow-up is conducted yearly on patients registered in the Montana Central Tumor Registry and is a necessary part of adequate care for cancer patients. It also provides valuable data for cancer end-results research. Follow-up ensures continued medical surveillance and assures that cancer patients continue to see a physician for examination at least once a year. Meaningful end-result reporting can only be accomplished when a follow-up program is highly successful.

A central registry allows a hospital and its physicians to compare their cancer patient experiences and outcomes in managing certain types of cancer with results experienced elsewhere in the state.

History of the Montana Central Tumor Registry

The Montana Central Tumor Registry has had a long, but sporadic, history. A number of Montana physicians, medical record staff, and other organizations have contributed to the database that exists today.

The first effort at a Montana tumor registry began in the 1950s. It was called the Mary Swift Tumor Clinic in Butte, MT and it was funded by a legacy donation. This registry contained mostly Butte residents and was under operation until 1983. Some of those patients are still registered on the Montana Central Tumor Registry today.

In 1970, the Montana Medical Education and Research Foundation, Mountain States Regional Medical Program, established a Central Tumor Registry. It existed only for 18 months. This was phased out after the federal government discontinued funding the program. These data were never used.

In 1975, the Montana Foundation for Medical Care attempted to re-establish the Tumor Registry, which only lasted another 18 months. This attempt failed not by choice of the participating hospitals, but because federal funds were once again eliminated. At that time, 33 hospitals were voluntarily participating in the program. Again, these data were never used.

In 1979, the Montana Legislature approved funding for the Montana Central Tumor Registry for two years. It was under the direction of the Department of Health and Environmental Sciences (DHES). Although the hospitals were concerned about the possible collapse of funding again, the program won the confidence of 46 hospitals that were willing to contribute their cancer data in order to provide uniform statewide cancer reporting.

Based largely on the favorable experience reported to it, the 1981 Montana Legislature continued funding the Montana Central Tumor Registry and made cancer a reportable disease, requiring all hospitals in the state to report their cancer cases.

The 1983 Montana Legislature approved House Bill 113, which provided for cancer reporting by independent clinical laboratories in addition to hospitals. This was important in helping the Montana Central Tumor Registry obtain more complete, reliable statistics and in furthering the objective of a valid population-based cancer registry for the state.

The 1997 Montana Legislature approved House Bill 370, which provided for cancer reporting from physicians or other health care practitioners who diagnose and/or treat patients without referring them to a hospital. The purpose of this addition to the law was to obtain even more complete cancer reporting. Currently, physicians provide diagnostic and treatment information on cases queried by the Montana Central Tumor Registry.

In 2008, the Montana Central Tumor Registry initiated a rules change under the Montana Procedures Act to modify several existing reporting rules ARM 37.8.1801 - 1802. The modified rules apply to cancer cases reported to the Montana Central Tumor Registry starting in 2009. The rules updated reportable ambiguous terms, clarified reporting timeliness, required reporting of physical address, Hispanic origin, supporting text, recurrence date, payer, occupation, industry, tobacco history, and alcohol history.

Data Collection

The Montana Central Tumor Registry collects data on all cancer patients who are residents of Montana or residents of other states who are diagnosed and/or treated for cancer in Montana. The Montana Central Tumor Registry has many interstate exchange agreements with other states where Montana residents may go for diagnosis or treatment of cancer and is able to collect data from those states. Residents of other states are not included in this report. As of August 2009, there are about 148,000 cases registered on the Montana Central Tumor Registry.

Reportable Cancer Cases

According to the Administrative Rules of Montana (37.8.1801), the following tumors are to be submitted for reporting. Hospitals and physicians are required to submit reportable cancer cases to the Montana Central Tumor Registry within six months after the patient is first seen with cancer.

- A. All malignant neoplasms (including in-situ)

EXCEPTION: Basal Cell Carcinoma or Squamous Cell Carcinoma of the skin.

NOTE: BCC and SCC of the labia, vagina, vulva, clitoris, penis, scrotum, prepuce, and anus must be included. Carcinoma in-situ of the cervix (CIS), intraepithelial neoplasia grade III (8077/2) of the cervix (CIN III), prostate (PIN III), vulva (VIN III), vagina (VAIN III), and anus (AIN III) are required by the Montana Central Tumor Registry because of their in-situ classification.

- B. All benign tumors of the brain

INCLUDES: meninges, brain, spinal cord, cranial nerves and other parts of the CNS, pituitary gland, craniopharyngeal duct, and pineal gland

- C. All carcinoid tumors (malignant, benign, and NOS)

- D. Ambiguous Terms (terms that constitute diagnoses that are not histologically confirmed)

Apparent(ly)	Appears	Comparable with
Compatible with	Consistent with	Favor(s)
Malignant appearing	Most likely	Presumed
Probable	Suspect(ed)	Suspicious (for)
Typical (of)		

Quality Assurance of Data Collected

Accuracy and consistency are essential in tumor registry reporting. The Montana Central Tumor Registry performs quality control review on all abstracts and follow-ups received. Procedures for review include visual review, computerized data edits, and hospital or physician queries.

The Montana Central Tumor Registry will perform quality assurance tasks upon receipt of abstracts from each reporting institution. Periodic review procedures also include re-abstracting of cases and casefinding studies. The reporting facility is required to resolve incomplete, incorrect, or inconsistent data upon Montana Central Tumor Registry query.

The Montana Central Tumor Registry Advisory Group was established in January 2009. The group was selected to help the Montana Central Tumor Registry develop best-practices for registry operations, submissions, changes, and reporting barriers. Experts in the registry field are used when needed. The group provides advice only; there are no responsibilities for those selected. The group meets twice yearly and presently consists of experienced and new registrars and Montana Central Tumor Registry staff.

Registry Certification

The Montana Central Tumor Registry submits data annually to the North American Association of Central Cancer Registries (NAACCR) for evaluation and certification. This submission is required because of our cooperative agreement with the CDC and its purpose is two-fold.

The first purpose is to recognize population based registries that have achieved excellence in the areas of completeness of case ascertainment, quality of the data, and timeliness.

Secondly, the purpose is to provide confidential feedback which individual registries can use to identify current and future resource and training needs.

Silver or Gold certification of incidence data is required to publish the cancer data in Cancer in North America: 1995-2006, Volumes I (Incidence), II (Mortality), and III (Combined U.S. Incidence).

The Montana Central Tumor Registry has met Gold or Silver Certification standards since 1999. Obtaining Gold or Silver certification reflects the ongoing efforts of all the facilities that report complete, timely, and quality cancer data to the Montana Central Tumor Registry. Below are our results by year:

<u>Year of Data</u>	<u>Certification Results</u>
1999	Silver
2000	Silver
2001	Silver
2002	Silver
2003	Gold
2004	Gold
2005	Gold
2006	Silver

NAACCR Registry Certification on Quality, Completeness, and Timeliness Summary of Certification Measures		
Registry Element	Gold Standard	Silver Standard
1. Completeness of case ascertainment	95%	90%
2. Completeness of information		
Missing/Unk "age at diagnosis"	<=2%	<=3%
Missing/Unk "sex"	<=2%	<=3%
Missing/Unk "race"	<=3%	<=5%
Missing/Unk "state/county"	<=2%	<=3%
3. Death Certificate Only cases	<=3%	<=5%
4. Duplicate primary cases	<=1 per 1000	<=2 per 1,000
5. Passing Edits	100%	97%
6. Timeliness	Data submitted within 23 months of close of year.	

Appendix B

Technical Notes and Definitions

Incidence and Mortality Rates

A population's burden of cancer depends in large part on its size and age distribution because cancer is generally, although not exclusively, a disease of middle age and older. Therefore, cancer incidence and mortality are reported as standardized rates: the number of cases or deaths per 100,000 people, age-adjusted to a reference population to minimize the effect of variation in age distributions between populations. Standardized rates can be compared between Montana and the United States as a whole, or between a given county and Montana as a whole. All incidence rates are standardized to the 2000 U.S. Standard Million Population by the direct method.⁸ Comparisons cannot be made between rates calculated from different reference populations.

Incidence rate: The cancer incidence rate is the number of new cases diagnosed during a specified time period, per 100,000 people (using the annual population estimates summed over the time period in the denominator). All incidence rates are calculated for invasive cancers only except for bladder, which are calculated for invasive and in-situ cancers. Basal cell carcinoma and squamous cell carcinoma of the skin were excluded.

Mortality rate: The mortality rate is the number of deaths occurring in the population during a specified time period, per 100,000 people (using the annual population estimates summed over the time period in the denominator). The U.S. mortality data were provided by the National Program of Cancer Registries of the Centers for Disease Control and Prevention and published in the United States Cancer Statistics (USCS).

95% Confidence Intervals

Confidence intervals (95%) are provided for all computed rates for Montana. The confidence intervals provide information regarding the reliability of the estimates. There is a 95% probability that the true value of the incidence or mortality rate lies within the interval.

Risk Factors

Risk factors are listed in the site-specific cancer summaries for the four most common cancers, cervical cancer, and all sites combined. These listings briefly summarize information from a few selected references. Cancers are complex diseases and have multiple factors contributing to their development. The risk factors presented in this report are not intended to be a definitive and comprehensive list; rather they are a starting point for the interested reader. Risk factors may change with continuing research.

⁸ See Appendix F. See also R. N. Anderson and H. M. Rosenberg, Age Standardization of Death Rates: Implementation of the Year 2000 Standard. National Vital Statistics Report, Vol 47, no. 3. Hyattsville, MD: National Center for Health Statistics, 1998.

Data Limitations

Montana is a sparsely populated state, with a total estimated population of 902,195 in the year 2000 and a population density of approximately 6 per square mile. County population sizes ranged from 493 in Petroleum County to 129,352 in Yellowstone County in the 2000 census.

Because of the low population numbers and relative rarity of some forms of cancer, the numbers of cancer cases and cancer deaths can be very small. Small numbers are particularly problematic when data are subdivided by county, sex, or age. Aggregating data over a five-year period helps to offset the instability, but does not eliminate it. Caution must be exercised when examining incidence rates by county and incidences of relatively rare cancers. The size of county populations should be taken into consideration when examining incidence rates among counties.

National Rates

Incidence and mortality rates from the NPCR were used as estimates of U.S. rates for comparison to Montana rates. These data are published in the USCS and are available on the web at <http://apps.nccd.cdc.gov/uscs/>.

National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program were used as comparison for stage at diagnosis. SEER data are gathered from 11 geographic areas of the U.S. These geographic areas are considered by SEER to be "reasonably representative subsets of the United States Population."⁹

Age-specific Incidence Rates

Montana age-specific rates are calculated for five-year age groupings by dividing the number of cases by the total five-year population of that age group and are expressed as a rate per 100,000 people.

⁹ <http://seer.cancer.gov>

Appendix C









Stage at Diagnosis











The staging of cancers is based on the extent of disease, its extent of spread to surrounding tissue and/or regional lymph nodes, and the presence or absence of distant metastases. The stages in order of increasing spread are in-situ, localized, regional, and distant. The Montana Central Tumor Registry data contain the stage of diagnosis coded according to the *SEER Summary Staging Manual 2000* guidelines for cases diagnosed in 2003. Cases diagnosed 2004-2007 are coded according to the *AJCC Collaborative Staging System* version 01.03.00.

<u>In-situ</u>	A neoplasm that fulfills all the microscopic criteria for a malignancy but does not invade or penetrate surrounding tissue. It is non-invasive.
<u>Localized</u>	An invasive neoplasm confined entirely to the organ of origin.
<u>Regional</u>	A neoplasm that has extended beyond the limits of the organ of origin directly into the surrounding organs or tissues; into regional lymph nodes; or both direct extension and regional lymph node involvement.
<u>Distant</u>	A neoplasm that has spread to parts of the body remote from the primary tumor, either by direct extension or by discontinuous metastasis.
<u>Unstaged</u>	Information is not sufficient to assign a stage.

Frequency distributions of cases according to their stage at diagnosis are provided in the detailed summaries of all cancer sites combined and the 16 most common cancers (see Table 1, page 3), accounting for 91% of all cancers diagnosed in Montana, on the next two pages.

Stage at Diagnosis by Site, Montana Central Tumor Registry, 2003-2007





Appendix D
County Incidence Rates, All Sites Combined
2003-2007

All Sites Combined*			All Sites Combined*		
County of Residence	Rate per 100,000	95% CI for rates	County of Residence	Rate per 100,000	95% CI for rates
Montana	455.5	(449.6 - 461.3)			
Beaverhead	350.9	(299.0 - 402.7)	Madison	343.7	(290.5 - 396.9)
Big Horn	418.8	(363.2 - 474.5)	Meagher	509.8	(386.1 - 633.6)
Blaine	419.9	(350.6 - 489.2)	Mineral	489.8	(404.0 - 575.6)
Broadwater	477.7	(402.5 - 553.0)	Missoula	437.2	(418.0 - 456.4)
Carbon	-		Musselshell	502.1	(419.7 - 584.6)
Carter	-		Park	429.4	(387.5 - 471.4)
Cascade	449.7	(430.4 - 469.0)	Petroleum	-	
Chouteau	478.5	(406.1 - 550.8)	Phillips	425.5	(351.9 - 499.1)
Custer	540.9	(486.1 - 595.7)	Pondera	532.5	(456.0 - 609.1)
Daniels	-		Powder River	-	
Dawson	566.8	(502.2 - 631.4)	Powell	397.5	(336.1 - 459.0)
Deer Lodge	408.9	(357.6 - 460.3)	Prairie	-	
Fallon	465.5	(363.7 - 567.3)	Ravalli	417.0	(391.3 - 442.7)
Fergus	533.8	(482.2 - 585.3)	Richland	370.1	(318.5 - 421.7)
Flathead	503.6	(482.8 - 524.5)	Roosevelt	490.7	(426.9 - 554.5)
Gallatin	398.9	(376.6 - 421.2)	Rosebud	479.8	(411.5 - 548.0)
Garfield	-		Sanders	483.2	(432.5 - 534.0)
Glacier	476.9	(420.0 - 533.8)	Sheridan	363.6	(294.9 - 432.2)
Golden Valley	-		Silver Bow	321.9	(297.0 - 346.9)
Granite	428.1	(332.9 - 523.3)	Stillwater	481.6	(421.0 - 542.3)
Hill	495.0	(446.6 - 543.3)	Sweet Grass	421.1	(339.2 - 503.0)
Jefferson	411.3	(355.2 - 467.3)	Teton	420.0	(355.5 - 484.5)
Judith Basin	504.8	(387.1 - 622.5)	Toole	454.5	(378.5 - 530.5)
Lake	438.1	(406.1 - 470.2)	Treasure	-	
Lewis & Clark	459.0	(434.9 - 483.1)	Valley	500.1	(436.6 - 563.7)
Liberty	-		Wheatland	497.5	(377.7 - 617.4)
Lincoln	449.9	(412.7 - 487.1)	Wibaux	-	
McCone	-		Yellowstone	521.1	(504.6 - 537.6)

* Rates include all invasive cases plus bladder in-situ cases.

- Rates are suppressed if there were fewer than 5 cases or the relative standard error was 25% or greater.

Appendix E
Count of Cancers Reported by Anatomical Site and Sex
2003-2007

PRIMARY CANCER SITES	MALE	FEMALE	PRIMARY CANCER SITES	MALE	FEMALE
TOTAL, ALL CANCERS	12,873	11,128	Female Genital System		
Oral Cavity and Pharynx			Cervix	---	138
Lip	72	25	Uterus	---	634
Tongue	85	31	Ovary	---	378
Major Salivary gland	50	21	Vagina	---	17
Floor of Mouth	23	11	Vulva	---	73
Gum & Other Mouth	35	28	Other Female Genital Organs	---	17
Nasopharynx	12	7	Male Genital System		
Tonsil	68	13	Prostate	4,253	---
Oropharynx	17	7	Testis	129	---
Hypopharynx	21	5	Penis	18	---
Pharynx	9	-	Other Male Genital Organs	-	---
Digestive System			Urinary System		
Esophagus	194	57	Bladder	909	268
Stomach	182	108	Kidney & Renal Pelvis	404	239
Small Intestine	35	38	Ureter	13	8
Colon	807	873	Other Urinary Organs	-	-
Rectum & Rectosigmoid	407	263	Brain & Other Nervous System		
Anus & Anocanal	22	46	Brain	206	132
Liver & Intrahepatic Bile Duct	127	70	Other Nervous System	11	6
Gallbladder	12	30	Endocrine System		
Other Biliary	34	27	Thyroid Gland	122	406
Pancreas	314	286	Other Endocrine	22	19
Retroperitoneum	5	17	Lymphomas**		
Peritoneum	-	32	Hodgkin Lymphoma	70	43
Other Digestive Organs	6	7	Non-Hodgkin Lymphoma	539	410
Respiratory System			Multiple Myeloma	155	126
Nasal Cavity & Sinuses	18	7	Leukemias		
Larynx	123	45	Acute Lymphocytic	34	26
Lung & Bronchus	1,768	1,631	Chronic Granulocytic	141	98
Trachea & Pleura	7	-	Acute Myeloid	118	97
Bones & Joints	25	26	Chronic Myeloid	56	38
Soft Tissue	82	68	Other Leukemia	46	23
Skin			Eye	31	21
Melanoma	488	394	Unknown and Ill-defined Sites	501	417
Other Skin	22	31			
Breast	18	3,280			

* Malignant neoplasms include all invasive cases plus bladder-in-situ cases.

** Non-Hodgkin Lymphoma (NHL) and Hodgkin Lymphoma are not included in the anatomical site (e.g., lymphoma of the stomach is counted as a lymphoma, not stomach cancer).

- Counts are suppressed when fewer than 5 cases to ensure confidentiality and statistical reliability.

Appendix F
Montana Population by County, 2000*

FIPS Code	County Name	Male	Female	Total	Percent of Total Population
1	Beaverhead	4,713	4,489	9,202	1.0%
3	Big Horn	6,249	6,422	12,671	1.4%
5	Blaine	3,460	3,549	7,009	0.8%
7	Broadwater	2,236	2,149	4,385	0.5%
9	Carbon	4,785	4,767	9,552	1.1%
11	Carter	662	698	1,360	0.2%
13	Cascade	39,756	40,601	80,357	8.9%
15	Chouteau	2,997	2,973	5,970	0.7%
17	Custer	5,724	5,972	11,696	1.3%
19	Daniels	988	1,029	2,017	0.2%
21	Dawson	4,490	4,569	9,059	1.0%
23	Deer Lodge	4,703	4,714	9,417	1.0%
25	Fallon	1,434	1,403	2,837	0.3%
27	Fergus	5,787	6,106	11,893	1.3%
29	Flathead	36,911	37,560	74,471	8.3%
31	Gallatin	35,274	32,557	67,831	7.5%
33	Garfield	660	619	1,279	0.1%
35	Glacier	6,553	6,694	13,247	1.5%
37	Golden Valley	539	503	1,042	0.1%
39	Granite	1,450	1,380	2,830	0.3%
41	Hill	8,306	8,367	16,673	1.8%
43	Jefferson	5,045	5,004	10,049	1.1%
45	Judith Basin	1,209	1,120	2,329	0.3%
47	Lake	13,028	13,479	26,507	2.9%
49	Lewis & Clark	27,360	28,356	55,716	6.2%
51	Liberty	1,063	1,095	2,158	0.2%
53	Lincoln	9,542	9,295	18,837	2.1%
55	McCone	987	990	1,977	0.2%
57	Madison	3,465	3,386	6,851	0.8%
59	Meagher	968	964	1,932	0.2%
61	Mineral	2,000	1,884	3,884	0.4%
63	Missoula	47,875	47,927	95,802	10.6%
65	Musselshell	2,196	2,301	4,497	0.5%
67	Park	7,745	7,949	15,694	1.7%
69	Petroleum	259	234	493	0.1%
71	Phillips	2,305	2,296	4,601	0.5%
73	Pondera	3,169	3,255	6,424	0.7%
75	Powder River	916	942	1,858	0.2%
77	Powell	4,228	2,952	7,180	0.8%
79	Prairie	619	580	1,199	0.1%
81	Ravalli	17,910	18,160	36,070	4.0%
83	Richland	4,801	4,866	9,667	1.1%
85	Roosevelt	5,264	5,356	10,620	1.2%
87	Rosebud	4,712	4,671	9,383	1.0%
89	Sanders	5,166	5,061	10,227	1.1%
91	Sheridan	2,039	2,066	4,105	0.5%
93	Silver Bow	17,108	17,498	34,606	3.8%
95	Stillwater	4,178	4,017	8,195	0.9%
97	Sweet Grass	1,800	1,809	3,609	0.4%
99	Teton	3,174	3,271	6,445	0.7%
101	Toole	2,716	2,551	5,267	0.6%
103	Treasure	439	422	861	0.1%
105	Valley	3,802	3,873	7,675	0.9%
107	Wheatland	1,118	1,141	2,259	0.3%
109	Wibaux	513	555	1,068	0.1%
111	Yellowstone	63,084	66,268	129,352	14.3%
	Montana			902,195	

* U.S. Census Bureau Population.

Population Figures for Montana By Five-Year Age Groups and Year, 2003-2007

Males					
Age Group	2003	2004	2005	2006	2007
0-4	28,412	28,670	28,979	29,699	30,253
5-9	29,462	29,203	29,227	29,299	29,651
10-14	33,812	33,415	32,574	32,028	31,451
15-19	36,025	35,583	35,324	34,950	34,795
20-24	35,548	36,334	36,655	37,175	36,654
25-29	26,344	27,860	29,665	31,626	33,811
30-34	26,422	26,493	26,651	26,291	26,580
35-39	28,087	27,398	27,013	27,761	28,086
40-44	35,481	34,827	33,577	32,191	30,746
45-49	37,633	37,541	37,713	37,589	37,495
50-54	35,552	36,491	37,399	38,052	38,356
55-59	28,128	29,924	31,749	33,956	34,804
60-64	21,849	22,883	23,785	24,636	26,858
65-69	16,624	17,155	17,663	18,288	19,081
70-74	14,038	13,931	13,935	14,029	14,366
75-79	11,171	11,344	11,587	11,623	11,585
80-84	7,783	7,892	7,971	8,138	8,171
85+	5,656	5,911	6,213	6,509	6,890
Total	458,027	462,855	467,680	473,840	479,633

Females					
Age Group	2003	2004	2005	2006	2007
0-4	26,867	27,262	27,818	28,180	28,864
5-9	27,801	27,787	27,524	27,693	27,807
10-14	32,422	31,817	30,929	30,223	29,746
15-19	33,005	32,752	32,773	32,634	32,594
20-24	31,835	32,295	32,448	32,623	31,847
25-29	24,832	26,337	27,869	29,239	31,246
30-34	25,988	25,641	25,530	25,385	25,662
35-39	28,833	27,863	27,623	27,845	28,026
40-44	36,701	36,098	34,618	33,191	32,010
45-49	38,591	38,641	38,803	39,047	38,484
50-54	34,404	35,806	37,033	37,955	38,914
55-59	26,765	28,553	30,470	32,632	33,626
60-64	21,494	22,417	23,276	23,954	25,917
65-69	17,385	17,866	18,194	18,758	19,440
70-74	15,745	15,511	15,497	15,562	15,686
75-79	13,842	13,896	14,130	14,089	14,063
80-84	11,364	11,461	11,321	11,365	11,345
85+	11,552	11,863	12,248	12,580	12,951
Total	459,426	463,866	468,104	472,955	478,228

2000 Standard Million Population Figures By Five-Year Age Groups

Age Group	Population
0-4	69,135
5-9	72,533
10-14	73,032
15-19	72,169
20-24	66,478
25-29	64,529
30-34	71,044
35-39	80,762
40-44	81,851
45-49	72,118
50-54	62,716
55-59	48,454
60-64	38,793
65-69	34,264
70-74	31,773
75-79	26,999
80-84	17,842
85+	15,508
Total	1,000,000

Source: SEER Program, National Cancer Institute, 2003.

Appendix G
Standard Site Analysis Categories
ICD-O-3 Codes by Anatomical Site

Site Group	ICD-O-3 Site Codes	ICD-O-3 Histology (Type)
Oral Cavity and Pharynx		
Lip	C000-C009	Excluding 9590-9989, and sometimes 9050-9055, 9140+
Tongue	C019-C029	
Salivary Gland	C079-C089	
Floor of Mouth	C040-C049	
Gum and Other Mouth	C030-C039, C050-C059, C060-C069	
Nasopharynx	C110-C119	
Tonsil	C090-C099	
Oropharynx	C100-C109	
Hypopharynx	C129, C130-C139	
Other Oral Cavity and Pharynx	C140, C142-C148	
Digestive System		
Esophagus	C150-C159	Excluding 9590-9989, and sometimes 9050-9055, 9140+
Stomach	C160-C169	
Small Intestine	C170-C179	
Colon	C180-C189, C260	
Rectum & Rectosigmoid	C199-C209	
Anus, Anal Canal, and Anorectum	C210-C212, C218	
Liver	C220	
Intrahepatic Bile Duct	C221	
Gallbladder	C239	
Other Biliary	C240-C249	
Pancreas	C250-C259	
Retroperitoneum	C480	
Peritoneum, Omentum, and Mesentery	C481-C482	
Other Digestive Organs	C268-C269, C488	
Respiratory System		
Nose, Nasal Cavity, and Middle Ear	C300-C301, C310-C319	Excluding 9590-9989, and sometimes 9050-9055, 9140+
Larynx	C320-C329	
Lung and Bronchus	C340-C349	
Pleura	C384	
Trachea, Mediastinum, and Other Respiratory Organs	C339, C381-C383, C388, C390, C398, C399	
Bones and Joints	C400-C419	Excluding 9590-9989, and sometimes 9050-9055, 9140+
Soft Tissue Including Heart	C380, C470-C479, C490-C499	Excluding 9590-9989, and sometimes 9050-9055, 9140+

Site Group	ICD-O-3 Site Codes	ICD-O-3 Histology (Type)
Skin Excluding Basal and Squamous		
Melanoma of the Skin	C440-C449	8720-8790
Other Non-Epithelial Skin	C440-C449	Excluding 8000-8005, 8010-8045, 8050-8084, 8090-8110, 8720-8790, 9590-9989, and sometimes 9050-9055, 9140+
Breast	C500-C509	Excluding 9590-9989, and sometimes 9050-9055, 9140+
Female Genital System		
Cervix Uteri	C530-C539	Excluding 9590-9989, and sometimes 9050-9055, 9140+
Corpus Uteri and Uterus	C540-C549, C559	
Ovary	C569	
Vagina	C529	
Vulva	C510-C519	
Other Female Genital Organs	C570-C589	
Male Genital System		
Prostate	C619	Excluding 9590-9989, and sometimes 9050-9055, 9140+
Testis	C620-C629	
Penis	C600-C609	
Other Male Genital Organs	C630-C639	
Urinary System		
Urinary Bladder	C670-C679	Excluding 9590-9989, and sometimes 9050-9055, 9140+
Kidney and Renal Pelvis	C649, C659	
Ureter	C669	
Other Urinary Organs	C680-C689	
Eye and Orbit	C679-C699	Excluding 9590-9989, and sometimes 9050-9055, 9140+
Brain and Other Nervous System		
Brain	C710-C719	Excluding 9590-9989, and sometimes 9050-9055, 9140+
Cranial Nerves and Other Nervous System	C710-C719	9530-9539
	C700-C709, C720-C729	Excluding 9590-9989, and sometimes 9050-9055, 9140+
Endocrine System		
Thyroid	C739	Excluding 9590-9989, and sometimes 9050-9055, 9140+
Other Endocrine Including Thymus	C379, C740-C749, C750-C759	
Lymphoma		
Hodgkin Lymphoma		
Hodgkin - Nodal	C024, C098-C099, C111, C142, C379, C422, C770-C779	9650-9667
Hodgkin - Extranodal	All Other Sites	

Site Group	ICD-O-3 Site Codes	ICD-O-3 Histology (Type)
<i>Non-Hodgkin Lymphoma</i>		
NHL - Nodal	C024, C098-C099, C111, C142, C379, C422, C770-C779	9590-9596, 9670-9671, 9673, 9675, 9678-9680, 9684, 9687, 9689-9691, 9695, 9698-9702, 9705, 9708-9709, 9714-9719, 9727-9729, 9823, 9827
NHL - Extranodal	All sites except C024, C098-C099, C111, C142, C379, C422, C770-C779	9590-9596, 9670-9671, 9673, 9675, 9678-9680, 9684, 9687, 9689-9691, 9695, 9698-9702, 9705, 9708-9709, 9714-9719, 9727-9729
	All sites except C024, C098-C099, C111, C142, C379, C422, C770-C779	9823, 9827
Myeloma		9731-9732, 9734
Leukemia		
<i>Lymphocytic Leukemia</i>		
Acute Lymphocytic Leukemia		9826, 9835-9837
Chronic Lymphocytic Leukemia	C420, C421, C424	9823
Other Lymphocytic Leukemia		9820, 9832-9834, 9940
<i>Myeloid and Monocytic Leukemia</i>		
Acute Myeloid Leukemia		9840, 9861, 9866, 9867, 9871-9874, 9895-9897, 9910, 9920
Acute Monocytic Leukemia		9891
Chronic Myeloid Leukemia		9863, 9875, 9876, 9945, 9946
Other Myeloid/Monocytic Leukemia		9860, 9930
<i>Other Leukemia</i>		
Other Acute Leukemia		9801, 9805, 9931
Aleukemic, Subleukemic, and NOS		9733, 9742, 9800, 9831, 9870, 9948, 9963, 9964
	C420, C421, C424	9827
Mesothelioma		9050-9055
Kaposi Sarcoma		9140
Miscellaneous		9740-9741, 9750-9758, 9760-9769, 9950, 9960-9962, 9970, 9975, 9980, 9982-9987, 9989
	C760-C768, C809	Excluding 9590-9989, and sometimes 9050-9055, 9140+
	C420-C424	
	C770-C779	

Appendix H Resources

For more information about the cancers described here, please refer to the following resources:

Schottenfeld D, Fraumeni J (eds). *Cancer Epidemiology and Prevention*, 3rd ed. Oxford University Press, New York: 2006.

Horner MJ, Ries LAG, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK (eds). *SEER Cancer Statistics Review, 1975-2006*, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.

U.S. Cancer Statistics Working Group. *United States Cancer Statistics: 1999-2005 Incidence and Mortality Web-based Report*. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2009. Available at: www.cdc.gov/uscs.

National Cancer Institute. <http://www.cancer.gov>.

Please visit our website at www.cancer.mt.gov.

For more information about the **Montana Cancer Control Program**, contact Ginny Furshong, Program Manager, 406-444-6888, gfurshong@mt.gov.

For more information about the **Montana Breast and Cervical Health Program**, contact Mark Wamsley, Program Manager, 406-444-3385, mwamsley@mt.gov.

For more information about the **Cancer Surveillance and Epidemiology Program**, contact Carol Ballew, PhD, Program Manager, 406-444-6988, cballew@mt.gov.

For more information about the **Montana Central Tumor Registry**, contact Debbi Lemons, Coordinator, 406-444-6786, dlemons@mt.gov.

Alternative formats of this document will be provided upon request. Please contact Dr. Ballew.

Montana Cancer Control Program
Montana Department of Health and Human Services
1400 Broadway C-317, PO Box 202951
Helena, MT 59620-2951